Results 41 to 50 of about 141,956 (266)

Цитогенетические повреждения и эпигенетический статус промоторов генов TP53, BRCA1 и ERCC2 у работников угольных предприятий [PDF]

Письма в Вавиловский журнал генетики и селекции
Человек подвергается воздействию различных химических соединений на протяжении жизни, однако профессиональная специализация обуславливает наиболее опасное воздействие на организм. Важной проблемой является понимание влияния промышленной среды на геномную
Марущак А.В, Астафьева М.В, Глушков А.Н., Минина В.И.   +3 more
doaj   +1 more source

Dual PI3K/AKT and CDK4/6 inhibition reveals selective sensitivity in an SHH medulloblastoma stem cell model

Molecular Oncology, EarlyView.
Targeted therapy was evaluated in SHH medulloblastoma using neuroepithelial stem cell (NES) and tumor‐derived NES‐like (tNES) models in 2D monolayers and 3D spheroids. PI3K, AKT, and CDK4/6 inhibitors had minimal effects in NES but markedly reduced viability and growth and induced apoptosis in tNES cells, revealing distinct therapeutic vulnerabilities.
Monika Lukoseviciute, Madeleine Birgersson, Paolo Ceriani, Margareta Wilhelm, Ourania N Kostopoulou   +4 more
wiley   +1 more source

بررسی جهش در اگزو نهای پنج تا هشت ژن TP53 در بیماران آذری مبتلا به سرطان تیروئید تک گیر [PDF]

مجله دانشگاه علوم پزشکی سبزوار, 2018
چکیده:سابقه و هدف : سرطان تیروئید شایع‌ترین بدخیمی سیستم اندوکرینی است. سرطان تیروئید در هر سن و جنس می‌تواند رخ دهد. از مهمترین ژن‌های سرکوبگر درگیر در سرطان، ژن TP53 می‌باشد. که در تنظیم و توقف چرخه سلولی و اپوتپوز نقش مهمی دارد.
ناصر پولادی, محمدعلی حسینپور فیضی   +1 more
doaj  

The Efficacy and Safety of PD-1 Inhibitors Combined with Nab-Paclitaxel Plus Gemcitabine versus Nab-Paclitaxel Plus Gemcitabine in the First-Line Treatment of Advanced Pancreatic Cancer: A Retrospective Monocentric Study

Cancer Management and Research, 2022
Feng Zhang, Yuyang Wang, Fangfang Yang, Yuming Zhang, Man Jiang,* Xiaochun Zhang* Precision Medicine Center of Oncology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266003, People’s Republic of China*These ...
Zhang F, Wang Y, Yang F, Zhang Y, Jiang M, Zhang X   +5 more
doaj  

Two Subsequent Metachroneus Solid Tumors: Oncocytic Variant Adrenocortical Carcinoma and Rhabdomyosarcoma of Childhood: Case Report and Literature Review

JCRPE, 2021
Most cases of malignancies appear to be sporadic, but some syndromes are associated with malignancies with germline variants. Herein, a child with an unusual association of oncocytic variant adrenocortical carcinoma (ACC) and rhabdomyosarcoma (RMS) was ...
Onur Akin, Erman Atas, İrem Ayşe Atasoy, Nihal Durmaz, Ömer Kartal   +4 more
doaj   +1 more source

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?

HemaSphere, 2023
International ...
openaire   +4 more sources

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

Molecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena, Karin Teien Lande, Eva Diaz, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Alicia Abalo, Nerea González, Eva Colás, Antonio Gil‐Moreno, Miguel Abal, Gema Moreno‐Bueno, Therese Sørlie, Kristina Lindemann, Laura Muinelo‐Romay   +15 more
wiley   +1 more source

Quantitative Analysis of TP53-Related Lung Cancer Based on Radiomics

International Journal of General Medicine, 2022
Hongyu Qiao,1 Zhongxiang Ding,2 Youcai Zhu,1 Yuguo Wei,3 Baochen Xiao,1 Yongzhen Zhao,1 Qi Feng2 1Zhejiang Rongjun Hospital, Jiaxing, People’s Republic of China; 2Department of Radiology, Affiliated Hangzhou First People’s Hospital, Zhejiang University ...
Qiao H, Ding Z, Zhu Y, Wei Y, Xiao B, Zhao Y, Feng Q   +6 more
doaj  

Relevance of TP53 for CLL diagnostics [PDF]

Journal of Clinical Pathology, 2019
TP53 disruption in chronic lymphocytic leukaemia (CLL) is a well-established prognostic marker and informs on the appropriate course of treatment for patients. TP53 status is commonly assessed by fluorescence in situ hybridisation for del(17 p) and Sanger sequencing for
Mark A Catherwood, David Gonzalez, David Donaldson, Ruth Clifford, Ken Mills, Patrick Thornton   +5 more
openaire   +3 more sources

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source